進行腎細胞がんの市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Advanced Renal Cell Carcinoma Market Insights, Epidemiology and Market Forecast-2028
◆商品コード:DATA00109007
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥712,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,137,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Advanced Renal Cell Carcinoma Market Insights, Epidemiology and Market Forecast-2028
DelveInsight’s ‘Advanced Renal Cell Carcinoma- Market Insights, Epidemiology and Market Forecast—2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Advanced Renal Cell Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Advanced Renal Cell Carcinoma from 2017 to 2028 segmented by G8 countries. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
• China

Study Period: 2017–2028
Advanced Renal Cell Carcinoma – Disease Understanding and Treatment Algorithm

Renal cell carcinoma (RCC), also called renal cell cancer or renal cell adenocarcinoma, which has almost all type of kidney cancers. RCC usually begins as a tumor growing in one of the kidneys which can easily develop in both the kidneys, at times it can also be advanced or metastatic and can easily spread to the other part of the body. Renal cancer accounts for five percent, in men and women both, wherein it is the seventh most common cancer in men, and the tenth most in women. Over two decades of increasing rates, RCC incidence has shown an increase in recent years. The patterns are consistent with reports of incidental diagnosis and downward shift of tumor stage and size.

When RCC is in its early stages, patients may be symptom free but as the disease progresses, symptoms may include a lump in the abdomen, blood in the urine, unexplained weight loss, loss of appetite, fatigue, vision problems, excessive hair growth (in women), etc.

The renal cell carcinoma on the basis of the location and cellular lining and the pathway followed by the tumor for the growth is historically divided into various sub types such as Clear cell RCC, Papillary RCC, Chromophobe RCC, Collecting duct RCC and Unclassified RCC.

The DelveInsight Advanced Renal Cell Carcinoma market report gives the thorough understanding of the Advanced Renal Cell Carcinoma by including details such as disease introduction, biology and pathology, pathophysiology, risk Factors, mechanisms, staging, epigenetics, biomarkers, diagnosis and diagnostic guidelines of Advanced Renal Cell Carcinoma.

Advanced Renal Cell Carcinoma Epidemiology

According to the National Organization of Rare Disorders (NORD), renal cell carcinoma accounts for approximately 30,000 new cases of kidney malignancies per year in the United States. It is more common in males than in females (ratio of 2–3:1) and in persons with a history of smoking.

Renal cell carcinomas (RCC) are primary malignant adenocarcinomas derived from the renal tubular epithelium and are the most common malignant renal tumor. They usually occur in 50–70 year old patients and macroscopic hematuria occurs in 60% of the cases.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Advanced Renal Cell Carcinoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028 for the following aspects:

• Diagnosed Incident Cases of Renal Cell Carcinoma (RCC)
• Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
• Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC)
• Stage-specific Diagnosed Incident Cases of RCC
• Total Cases of Advanced/Metastatic RCC

Dutcher et al. conducted a study titled “Update on the biology and management of renal cell carcinoma” which stated that renal cell cancer (RCC) (epithelial carcinoma of the kidney) represents 2–4% of newly diagnosed adult tumors. Despite the increased detection of small renal masses of variable clinical significance, 25–30% of patients with RCC present with metastatic disease.

Schwab et al. conducted a study titled “mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma – A German Single-center Real-world Experience” suggesting that RCC had an incidence of 14,956 patients in 2014 with a high mortality rate of 5,278 patients in Germany.

Advanced Renal Cell Carcinoma Drug Chapters

This segment of the Advanced Renal Cell Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Advanced Renal Cell Carcinoma, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of Advanced Renal Cell Carcinoma & awareness of the disease. The overall dynamics of Advanced Renal Cell Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Merck, Genentech, Eisai, Bristol-Myers Squibb, Pfizer, X4 Pharmaceuticals and others will significantly increase the market during the forecast period (2019–2028).
Advanced Renal Cell Carcinoma Market Outlook

The Advanced Renal Cell Carcinoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Currently there are a number of treatment options available to treat the patients with advanced RCC. The treatment ranges from excising out the tumor to using pharmacological interventions. The treatment options for advanced RCC include Surgery and Pharmacological interventions of various classes such as VEGF Inhibitors (Inlyta, Lenvima, Sutent, Cabometyx, Avastin, Votrient and Nexavar), PD-1/PD-L1 inhibitors (Keytruda, Opdivo, Bavencio), CTLA-4 inhibitors (Yervoy) and monoclonal antibodies. Surgery is opted for the condition where the tumor is localized to the kidney but also in some cases of metastasis, more advanced and regress protocols are followed in the surgical process. Various surgical procedures are opted to excise out the tumor lesions such as Partial nephrectomy (PN), Radical Nephrectomy, Cytoreductive Nephrectomy, Radiofrequency ablation and Cryoablation. Pharmacological therapies are the mainstay treatment option followed by the patients with advanced renal cell carcinoma. The market of advanced RCC includes use of the drugs either as monotherapies or in combination. The market of advanced RCC comprises of several approved drugs both as monotherapies and in combination.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Advanced Renal Cell Carcinoma in the G8 countries is expected to change from 2019–2028.

Advanced Renal Cell Carcinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Advanced Renal Cell Carcinoma such as Atezolizumab + Bevacizumab (Merck and Genentech), Pemrolizumab + Lenvima (Merck/Eisai), Crizotinib (Pfizer), X4P-001 + Axitinib (X4 Pharmaceuticals) and other targeted therapies in the forecast period [2019–2028] will also create a positive impact on the Advanced Renal Cell Carcinoma market.

Advanced Renal Cell Carcinoma Report Insights

• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Advanced Renal Cell Carcinoma Report Key Strengths

• 10 Year Forecast
• G8 Countries Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Advanced Renal Cell Carcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Advanced Renal Cell Carcinoma market.
• Organize sales and marketing efforts by identifying the best opportunities for Advanced Renal Cell Carcinoma market.
• To understand the future market competition in the Advanced Renal Cell Carcinoma market.

Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report.

【レポートの目次】

1. Key Insights
2. Advanced Renal Cell Carcinoma (RCC) Market Overview at a Glance
2.1. Market Share (%) Distribution of Advanced Renal Cell Carcinoma (RCC) in 2017
2.2. Market Share (%) Distribution of Advanced Renal Cell Carcinoma (RCC) in 2028
3. Disease Background and Overview: Advanced Renal Cell carcinoma
3.1. Introduction
3.2. Histologic Subtypes and Related Molecular Pathways
3.2.1. Clear Cell Renal Cell Carcinoma
3.2.2. Non-clear-cell renal cell carcinomas
3.3. Biology and pathology of renal cell carcinoma
3.4. Pathophysiology
3.5. Risk Factors of Advanced Renal Cell Carcinoma
3.6. Mechanisms of Renal Cell Carcinoma
3.6.1. Genes and pathways
3.6.2. Tumor heterogeneity and cancer evolution
3.6.3. Immune infiltration and the tumor microenvironment
3.7. Staging of renal cell carcinoma
3.7.1. TNM Staging
3.7.2. Composite grading systems for renal carcinoma
3.7.3. Fuhrman Nuclear Grade
3.8. Genetic Pathology of renal cell carcinoma
3.8.1. Von Hippel–Lindau gene
3.8.2. Protein polybromo-1 gene
3.8.3. BRCA1-associated protein-1
3.8.4. The mTOR pathway
3.9. Epigenetics of RCC
3.10. Tumor Behavior and Prognostic Molecular Markers
3.11. Metabolic pathways and targets in renal cell carcinoma
3.11.1. The Glutaminase Pathway
3.11.2. Other metabolic pathways and targets
3.12. Role of the Immune System in Renal Cell Carcinoma
3.12.1. The programmed death-1 receptor (PD-1 receptor) pathway
3.12.2. Interaction between Angiogenesis and the Anti-Tumor Immune Response
3.13. Biomarkers
3.13.1. Molecular biomarkers
3.13.2. Inflammatory Proteins
3.13.3. Molecular Markers in Urine
3.14. Diagnosis
3.14.1. Size, Extent of Invasion Outside of the Kidney
3.14.2. Genomic implications
3.14.3. Histopathological confirmation
3.14.4. Radiologic Evaluation
3.14.5. Screening and Imaging
3.14.6. Preoperative Evaluation
3.15. Diagnostic Guidelines
3.15.1. European Association of Urology Guidelines on Renal Cell Carcinoma: 2019
3.15.2. Renal Mass and Localized Renal Cancer: AUA Guideline (2017)
3.15.3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis
3.16. Nutshell: Advanced Renal Cell Carcinoma
4. Recognized Establishments
4.1.1. United States
4.1.2. Europe
4.1.3. Japan
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. G8 Countries Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC)
6. Country Wise-Epidemiology of Advanced Renal Cell Carcinoma (RCC)
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in the United States
6.1.3. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in the United States
6.1.4. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in the United States
6.1.5. Stage-specific Diagnosed Incident Cases of RCC in the United States
6.1.6. Total Cases of Advanced/Metastatic RCC in the United States
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in Germany
6.3.2. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Germany
6.3.3. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Germany
6.3.4. Stage-specific Diagnosed Incident Cases of RCC in Germany
6.3.5. Total Cases of Advanced/Metastatic RCC in Germany
6.4. France
6.4.1. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in France
6.4.2. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in France
6.4.3. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in France
6.4.4. Stage-specific Diagnosed Incident Cases of RCC in France
6.4.5. Total Cases of Advanced/Metastatic RCC in France
6.5. Italy
6.5.1. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in Italy
6.5.2. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Italy
6.5.3. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Italy
6.5.4. Stage-specific Diagnosed Incident Cases of RCC in Italy
6.5.5. Total Cases of Advanced/Metastatic RCC in Italy
6.6. Spain
6.6.1. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in Spain
6.6.2. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Spain
6.6.3. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Spain
6.6.4. Stage-specific Diagnosed Incident Cases of RCC in Spain
6.6.5. Total Cases of Advanced/Metastatic RCC in Spain
6.7. United Kingdom
6.7.1. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in the United Kingdom
6.7.2. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in the United Kingdom
6.7.3. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in the United Kingdom
6.7.4. Stage-specific Diagnosed Incident Cases of RCC in the United Kingdom
6.7.5. Total Cases of Advanced/Metastatic RCC in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in Japan
6.8.3. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Japan
6.8.4. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in Japan
6.8.5. Stage-specific Diagnosed Incident Cases of RCC in Japan
6.8.6. Total Cases of Advanced/Metastatic RCC in Japan
6.9. China
6.9.1. Assumptions and Rationale
6.9.2. Diagnosed Incident Cases of Renal Cell Carcinoma (RCC) in China
6.9.3. Gender-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in China
6.9.4. Subtype-specific Diagnosed Incidence of Renal Cell Carcinoma (RCC) in China
6.9.5. Stage-specific Diagnosed Incident Cases of RCC in China
6.9.6. Total Cases of Advanced/Metastatic RCC in China
7. Treatment
7.1. Surgical management
7.1.1. Partial nephrectomy (PN)
7.1.2. Radical Nephrectomy
7.1.3. Cytoreductive Nephrectomy
7.1.4. Non-surgical tumor treatments
7.2. Systemic therapy
7.2.1. Immunotherapy
7.2.2. PD-L1 therapy
7.3. Targeted Therapy
7.3.1. Cytokine Therapy
7.3.2. Sorafenib
7.3.3. Sunitinib
7.3.4. Bevacizumab
7.3.5. Pazopanib
7.3.6. Axitinib
7.3.7. Cabozantinib
7.3.8. Temsirolimus
7.3.9. Rocapuldencel-T
7.3.10. Avelumab
7.3.11. Active surveillance and ablative therapies
7.4. Radiation Therapy
7.4.1. Stereotactic radiosurgery (SRS)
7.4.2. Intraoperative RT (IORT)
7.5. Renal cell carcinoma: ESMO Clinical Practice Guidelines for treatment and follow-up (2019)
7.5.1. Management of local/locoregional disease
7.5.2. Management of advanced/metastatic disease
7.5.3. Follow-up, long-term implications and survivorship
7.6. European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma (2018)
7.6.1. Recommendations for treatment of localised RCC and local treatment of mRCC
7.7. NCCN Guidelines Updates: Management of Metastatic Kidney Cancer (2019)
7.8. Treatment Algorithm
8. Unmet Needs
9. Marketed Drugs
9.1. Keytruda/Inlyta: Merck/Pfizer
9.1.1. Drug Description
9.1.2. Regulatory Milestones
9.1.3. Other Development Activities
9.1.4. Safety and Efficacy
9.1.5. Product Profile
9.2. Opdivo/Yervoy: Bristol-Myers Squibb
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other Development Activities
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Bavencio/Inlyta: Merck/Pfizer
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Other Development Activities
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. Lenvima/Afinitor: Eisai/Novartis
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Other Development Activities
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. Sutent: Pfizer
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Other Development Activities
9.5.4. Safety and Efficacy
9.5.5. Product Profile
9.6. Cabometyx: Exelixis
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Other Development Activities
9.6.4. Safety and Efficacy
9.6.5. Product Profile
9.7. Avastin: Genentech (Roche)
9.7.1. Drug Description
9.7.2. Regulatory Milestones
9.7.3. Other Development Activities
9.7.4. Safety and Efficacy
9.7.5. Current Pipeline Activity
9.7.6. Product Profile
9.8. Votrient: Novartis
9.8.1. Drug Description
9.8.2. Regulatory Milestones
9.8.3. Other Development Activities
9.8.4. Safety and Efficacy
9.8.5. Product Profile
9.9. Fotivda: AVEO Oncology
9.9.1. Drug Description
9.9.2. Regulatory Milestones
9.9.3. Other Development Activities
9.9.4. Safety and Efficacy
9.9.5. Product Profile
9.10. Nexavar: Bayer HealthCare Pharmaceuticals
9.10.1. Drug Description
9.10.2. Regulatory Milestones
9.10.3. Other Development Activities
9.10.4. Safety and Efficacy
9.10.5. Product Profile
9.11. Torisel: Pfizer
9.11.1. Drug Description
9.11.2. Regulatory Milestones
9.11.3. Other Development Activities
9.11.4. Safety and Efficacy
9.11.5. Product Profile
10. Emerging Drugs
10.1. Key Cross Competition
10.2. Other Combination Trials Key Cross Competition
10.3. Bempegaldesleukin (NKTR-214) and NKTR-262: Nektar Therapeutics
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. Vorolanib (CM082): Betta Pharmaceuticals/Xcovery Holdings
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Product Profile
10.5. Telaglenastat (CB-839): Calithera Biosciences
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.4. Product Profile
10.6. Savolitinib (AZD-6094): AstraZeneca
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Product Profile
10.7. Nintedanib: Boehringer Ingelheim Pharmaceuticals
10.7.1. Product Description
10.7.2. Clinical Development
10.7.3. Product Profile
10.8. Camrelizumab (SHR-1210): Jiangsu HengRui Medicine
10.8.1. Product Description
10.8.2. Clinical Development
10.8.3. Product Profile
10.9. Crizotinib: Pfizer
10.9.1. Product Description
10.9.2. Clinical Development
10.9.3. Product Profile
10.10. Activated CIK and CD3-MUC1 Bispecific Antibody: Benhealth Biopharmaceutical
10.10.1. Product Description
10.10.2. Other developmental activities
10.10.3. Clinical Development
10.10.4. Product Profile
10.11. Mavorixafor (X4P-001): X4 Pharmaceuticals
10.11.1. Product Description
10.11.2. Other Developmental Activities
10.11.3. Clinical Development
10.11.4. Product Profile
10.12. Ibrutinib/Nivolumab: Pharmacyclics/Bristol-Myers Squibb
10.12.1. Product Description
10.12.2. Clinical Development
10.12.3. Product Profile
10.13. Pembrolizumab (MK-3475)/ Bevacizumab: Merck/Genentech (Roche)
10.13.1. Clinical Development
10.13.2. Product Profile
11. Emerging Combination Products Profile
11.1. Nivolumab/Cabozantinib: Bristol-Myers Squibb/Exelixis
11.1.1. Current Pipeline Activity
11.2. Pembrolizumab/Epacadostat: Merck/Incyte Corporation
11.2.1. Current Pipeline Activity
11.3. Pembrolizumab/Denosumab: Merck/Amgen
11.3.1. Current Pipeline Activity
11.4. Pembrolizumab/Pegylated Interferon Alfa-2b/Ipilimumab: Merck/ Bristol-Myers Squibb
11.4.1. Current Pipeline Activity
11.5. Pazopanib + Interferon alpha 2A: Novartis
11.5.1. Current Pipeline Activity
11.6. Pembrolizumab/Cabozantinib: Merck/Exelixis
11.6.1. Current Pipeline Activity
11.7. Cabozantinib/Sunitinib: Exelixis/Pfizer
11.7.1. Current Pipeline Activity
11.8. Nivolumab/Tivozanib: Bristol-Myers Squibb/AVEO Oncology
11.8.1. Current Pipeline Activity
11.9. Lenvatinib/Pembrolizumab: Eisai/Merck
11.9.1. Current Pipeline Activity
12. What Experts Say?
13. Advanced Renal Cell Carcinoma (RCC): G8 Countries Market Analysis
13.1. Key Findings
13.2. Market Size of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries
14. The United States Market Outlook
14.1. United States
14.1.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
14.1.2. Current Market Size by Therapies
14.1.3. Emerging Market Size by Therapies
15. EU-5 Countries: Market Outlook
15.1. Germany
15.1.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
15.1.2. Current Market Size by Therapies
15.1.3. Emerging Market Size by Therapies
15.2. France
15.2.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
15.2.2. Current Market Size by Therapies
15.2.3. Emerging Market Size by Therapies
15.3. Italy
15.3.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
15.3.2. Current Market Size by Therapies
15.3.3. Emerging Market Size by Therapies
15.4. Spain
15.4.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
15.4.2. Current Market Size by Therapies
15.4.3. Emerging Market Size by Therapies
15.5. United Kingdom
15.5.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
15.5.2. Current Market Size by Therapies
15.5.3. Emerging Market Size by Therapies
16. Japan: Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
16.1.2. Current Market Size by Therapies
16.1.3. Emerging Market Size by Therapies
17. China: Market Outlook
17.1. China Market Size
17.1.1. Total Market size of Advanced Renal Cell Carcinoma (RCC)
17.1.2. Current Market Size by Therapies
17.1.3. Emerging Market Size by Therapies
18. Case Reports
18.1. Management of Older Patients with Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
18.2. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts
18.3. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Table 1 Types of Non-clear-cell renal cell carcinomas
Table 2 Histological features of papillary urothelial lesions
Table 3 Guidelines for the diagnosis of Renal Cell Carcinoma
Table 4 Total Diagnosed Incident Population of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries (2017–2028)
Table 5 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States (2017–2028)
Table 6 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States (2017–2028)
Table 7 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States (2017–2028)
Table 8 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States (2017–2028)
Table 9 Advanced/Metastatic RCC Total Cases in the United States (2017–2028)
Table 10 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany (2017–2028)
Table 11 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany (2017–2028)
Table 12 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany (2017–2028)
Table 13 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany (2017–2028)
Table 14 Advanced/Metastatic RCC Total Cases in Germany (2017–2028)
Table 15 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France (2017–2028)
Table 16 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France (2017–2028)
Table 17 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France (2017–2028)
Table 18 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France (2017–2028)
Table 19 Advanced/Metastatic RCC Total Cases in France (2017–2028)
Table 20 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy (2017–2028)
Table 21 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy (2017–2028)
Table 22 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy (2017–2028)
Table 23 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy (2017–2028)
Table 24 Advanced/Metastatic RCC Total Cases in Italy (2017–2028)
Table 25 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain (2017–2028)
Table 26 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain (2017–2028)
Table 27 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain (2017–2028)
Table 28 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain (2017–2028)
Table 29 Advanced/Metastatic RCC Total Cases in Spain (2017–2028)
Table 30 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom (2017–2028)
Table 31 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom (2017–2028)
Table 32 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom(2017–2028)
Table 33 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom (2017–2028)
Table 34 Advanced/Metastatic RCC Total Cases in the United Kingdom (2017–2028)
Table 35 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan (2017–2028)
Table 36 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan (2017–2028)
Table 37 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan (2017–2028)
Table 38 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan (2017–2028)
Table 39 Advanced/Metastatic RCC Total Cases in Japan (2017–2028)
Table 40 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China (2017–2028)
Table 41 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China (2017–2028)
Table 42 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China (2017–2028)
Table 43 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China (2017–2028)
Table 44 Advanced/Metastatic RCC Total Cases in China (2017–2028)
Table 45 Drugs of Renal cell carcinomas
Table 46 Drugs of Renal cell carcinomas
Table 47 Drugs of Renal cell carcinomas
Table 48 Lines of treatment in advanced renal cell carcinoma
Table 49 Clinical Trial Description
Table 50 Comparison of Emerging Drugs Under Development
Table 51 Comparison of Emerging Drugs Under Development
Table 52 Bempegaldesleukin, Clinical Trial Description
Table 53 Vorolanib (CM082), Clinical Trial Description
Table 54 Telaglenastat, Clinical Trial Description
Table 55 Savolitinib, Clinical Trial Description
Table 56 Nintedanib, Clinical Trial Description
Table 57 Crizotinib, Clinical Trial Description
Table 58 Camrelizumab (SHR-1210), Clinical Trial Description
Table 59 Activated CIK and CD3-MUC1 Bispecific Antibody, Clinical Trial Description
Table 60 Mavorixafor, Clinical Trial Description
Table 61 Ibrutinib/Nivolumab, Clinical Trial Description
Table 62 Pembrolizumab/Bevacizumab, Clinical Trial Description
Table 63 Clinical Trial Description
Table 64 Clinical Trial Description
Table 65 Clinical Trial Description
Table 66 Clinical Trial Description
Table 67 Clinical Trial Description
Table 68 Clinical Trial Description
Table 69 Clinical Trial Description
Table 70 Clinical Trial Description
Table 71 Clinical Trial Description
Table 72 G8 Countries Market Size of Advanced Renal Cell Carcinoma (RCC) in USD Million (2017–2028)
Table 73 United States Market Size of Advanced Renal Cell Carcinoma (RCC), USD Million (2017–2028)
Table 74 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in the US, in USD Million (2017–2028)
Table 75 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in the US, in USD Million (2017–2028)
Table 76 Germany Market Size of Advanced Renal Cell Carcinoma (RCC), USD Million (2017–2028)
Table 77 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Germany, in USD Million (2017–2028)
Table 78 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Germany, in USD Million (2017–2028)
Table 79 France Market Size of Advanced Renal Cell Carcinoma (RCC), USD Million (2017–2028)
Table 80 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in France, in USD Million (2017–2028)
Table 81 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in France, in USD Million (2017–2028)
Table 82 Italy Market Size of Advanced Renal Cell Carcinoma (RCC), USD Million (2017–2028)
Table 83 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Italy, in USD Million (2017–2028)
Table 84 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Italy, in USD Million (2017–2028)
Table 85 Spain Market Size of Advanced Renal Cell Carcinoma (RCC), USD Million (2017–2028)
Figure 1 VHL inactivation in ccRCC and its implication in targeted therapy
Figure 2 Cancer evolution and tumor heterogeneity in ccRCC
Figure 3 Von Hippel–Lindau gene (HIF1A and HIF2A are hydroxylated on proline residues and bind the pVHL, resulting in polyubiquitination of HIFA)
Figure 4 The mTOR–PI3K pathway.
Figure 5 Distinct signaling pathways involved in programmed death 1 (PD-1)/PD-L1 interaction in the tumor microenvironment
Figure 6 Cellular and molecular components of the tumor ecosystem that shape the tumor angiogenic landscape.
Figure 7 Stages of kidney cancer and recommended treatments
Figure 8 Total Diagnosed Incident Patient Population of Advanced Renal Cell Carcinoma (RCC) in the G8 Countries (2017–2028)
Figure 9 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United States (2017–2028)
Figure 10 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United States (2017–2028)
Figure 11 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United States (2017–2028)
Figure 12 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United States (2017–2028)
Figure 13 Advanced/Metastatic RCC Total Cases in the United States (2017–2028)
Figure 14 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Germany (2017–2028)
Figure 15 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Germany (2017–2028)
Figure 16 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Germany (2017–2028)
Figure 17 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Germany (2017–2028)
Figure 18 Advanced/Metastatic RCC Total Cases in Germany (2017–2028)
Figure 19 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in France (2017–2028)
Figure 20 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in France (2017–2028)
Figure 21 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in France (2017–2028)
Figure 22 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in France (2017–2028)
Figure 23 Advanced/Metastatic RCC Total Cases in France (2017–2028)
Figure 24 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Italy (2017–2028)
Figure 25 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Italy (2017–2028)
Figure 26 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Italy (2017–2028)
Figure 27 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Italy (2017–2028)
Figure 28 Advanced/Metastatic RCC Total Cases in Italy (2017–2028)
Figure 29 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Spain (2017–2028)
Figure 30 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Spain (2017–2028)
Figure 31 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Spain (2017–2028)
Figure 32 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Spain (2017–2028)
Figure 33 Advanced/Metastatic RCC Total Cases in Spain (2017–2028)
Figure 34 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in the United Kingdom (2017–2028)
Figure 35 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in the United Kingdom (2017–2028)
Figure 36 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in the United Kingdom(2017–2028)
Figure 37 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in the United Kingdom (2017–2028)
Figure 38 Advanced/Metastatic RCC Total Cases in the United Kingdom (2017–2028)
Figure 39 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in Japan (2017–2028)
Figure 40 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in Japan (2017–2028)
Figure 41 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in Japan (2017–2028)
Figure 42 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in Japan (2017–2028)
Figure 43 Advanced/Metastatic RCC Total Cases in Japan (2017–2028)
Figure 44 Renal Cell Carcinoma (RCC) Diagnosed Incident Cases in China (2017–2028)
Figure 45 Renal Cell Carcinoma (RCC) Gender-specific Diagnosed Incidence in China (2017–2028)
Figure 46 Renal Cell Carcinoma (RCC) Subtype-specific Diagnosed Incidence in China (2017–2028)
Figure 47 Renal Cell Carcinoma (RCC) Stage-specific Diagnosed Incident Cases in China (2017–2028)
Figure 48 Advanced/Metastatic RCC Total Cases in China (2017–2028)
Figure 49 T-cell activation by ipilimumab (anti-CTLA-4, site of action in the periphery/lymph nodes) and nivolumab (anti-PD-1, site of action in the tumor microenvironment). MHC, major histocompatibility complex; TCR, T-cell receptor.
Figure 50 Simultaneous inhibition of the PD-1/PD-L1 axis and VEGFR/VEGF had synergistic antitumor effects.
Figure 51 Angiogenesis pathway and targeted therapies in RCC.
Figure 52 Treatment Algorithm for RCC.
Figure 53 Unmet Needs of Advanced Renal Cell Carcinoma
Figure 54 G8 Countries Market Size of Advanced Renal Cell Carcinoma (RCC) in USD Million (2017–2028)
Figure 55 Market Size of Advanced Renal Cell Carcinoma (RCC) in the United States, USD Millions (2017–2028)
Figure 56 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in the US, in USD Million (2017–2028)
Figure 57 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in the US, in USD Million (2017–2028)
Figure 58 Market Size of Advanced Renal Cell Carcinoma (RCC) in Germany, USD Millions (2017–2028)
Figure 59 Market Size of Advanced Renal Cell Carcinoma (RCC) by therapies, in Germany, in USD Million (2017–2028)
Figure 60 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Germany, in USD Million (2017–2028)
Figure 61 Market Size of Advanced Renal Cell Carcinoma (RCC) in France, USD Millions (2017–2028)
Figure 62 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in France, in USD Million (2017–2028)
Figure 63 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in France, in USD Million (2017–2028)
Figure 64 Market Size of Advanced Renal Cell Carcinoma (RCC) in Italy, USD Millions (2017–2028)
Figure 65 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Italy, in USD Million (2017–2028)
Figure 66 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Italy, in USD Million (2017–2028)
Figure 67 Market Size of Advanced Renal Cell Carcinoma (RCC) in Spain, USD Millions (2017–2028)
Figure 68 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Spain, in USD Million (2017–2028)
Figure 69 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Spain, in USD Million (2017–2028)
Figure 70 Market Size of Advanced Renal Cell Carcinoma (RCC) in the United Kingdom, USD Millions (2017–2028)
Figure 71 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in the UK, in USD Million (2017–2028)
Figure 72 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in the United Kingdom, in USD Million (2017–2028)
Figure 73 Market Size of Advanced Renal Cell Carcinoma (RCC) in Japan, USD Millions (2017–2028)
Figure 74 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Japan, in USD Million (2017–2028)
Figure 75 Market size of Advanced Renal Cell Carcinoma (RCC) by therapies in Japan, in USD Million (2017–2028)
>



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[進行腎細胞がんの市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆